| EXAMINER NCT01896479 | Fase 4 | En marcha, sin reclutar |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy NCT03690388 | Fase 3 | En marcha, sin reclutar |
| Carcinoma hepatocelular NCT03755791 | Fase 3 | En marcha, sin reclutar |
| Carcinoma de células renales NCT03937219 | Fase 3 | En marcha, sin reclutar |
| Carcinoma urotelial, Carcinoma de células renales NCT03170960 | Fase 1 | En marcha, sin reclutar |
| Cáncer de próstata metastásico NCT04446117 | Fase 3 | En marcha, sin reclutar |
| Cáncer, Cáncer colorrectal NCT07620574 | Fase 3 | Reclutando por invitación |
| Carcinoma hepatocelular NCT01908426 | Fase 3 | Completado |
| Carcinoma de células renales NCT01865747 | Fase 3 | Completado |
| Tumor sólido, Cáncer NCT01553656 | Fase 1 | Completado |
| Cáncer de próstata NCT01995058 | Fase 2 | Interrumpido |
| Cáncer de próstata, Dolor NCT01522443 | Fase 3 | Interrumpido |
| Cáncer de próstata, Dolor NCT01605227 | Fase 3 | Completado |
| Insuficiencia hepática NCT01493869 | Fase 1 | Completado |
| Tumor sólido, Cáncer NCT00940225 | Fase 2 | Completado |
| Insuficiencia renal NCT01761773 | Fase 1 | Completado |
| Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse NCT01068782 | Fase 2 | Interrumpido |
| Expanded Access of Cabozantinib in Medullary Thyroid Cancer NCT01683110 | no aplica | Aprobado para comercializar |